Mechanistic description

Mechanistic Overview

Mitochondrial Calcium Buffering Enhancement via MCU Modulation starts from the claim that modulating MCU within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The mitochondrial calcium uniporter (MCU) represents a critical nexus in cellular bioenergetics and calcium homeostasis, particularly in neurons with high metabolic demands such as layer II stellate neurons of the entorhinal cortex. These neurons exhibit distinctive electrophysiological properties, including high-frequency firing patterns and extensive dendritic arborizations that create extraordinary calcium handling requirements. The MCU complex, comprising the pore-forming MCU subunit, regulatory proteins MICU1, MICU2, and MCUR1, along with essential MCU regulator (EMRE), orchestrates mitochondrial calcium uptake through the electrochemical gradient established by the electron transport chain. In stellate neurons, repetitive action potential firing leads to sustained elevation of cytosolic calcium through voltage-gated calcium channels, particularly L-type and N-type channels concentrated at synaptic terminals and dendritic spines. Under physiological conditions, mitochondrial calcium uptake via MCU serves dual functions: buffering cytosolic calcium transients and stimulating oxidative phosphorylation through activation of key dehydrogenases including pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and isocitrate dehydrogenase. This calcium-dependent stimulation of the tricarboxylic acid cycle enhances NADH production and ATP synthesis, meeting the elevated energy demands of active neurons. However, in neurodegenerative conditions, this delicate balance becomes disrupted. Chronic elevation of cytosolic calcium, often resulting from excitotoxicity, impaired calcium extrusion mechanisms, or altered calcium channel expression, overwhelms mitochondrial calcium handling capacity. When mitochondrial calcium levels exceed buffering thresholds, several deleterious cascades are initiated. Excessive mitochondrial calcium triggers opening of the mitochondrial permeability transition pore (mPTP), leading to mitochondrial swelling, cristae disorganization, and cytochrome c release. Simultaneously, calcium-dependent activation of mitochondrial phospholipase A2 and nitric oxide synthase generates reactive oxygen species and lipid peroxidation products that further compromise mitochondrial integrity. The specific vulnerability of layer II stellate neurons stems from their unique anatomical and physiological characteristics. These neurons serve as primary input processors from the hippocampus and exhibit theta-frequency resonance properties that require sustained high-frequency firing. Their extensive dendritic trees, spanning multiple cortical layers, create substantial calcium loads that must be efficiently managed. Enhanced MCU function would increase mitochondrial calcium buffering capacity while maintaining the calcium-dependent stimulation of ATP production, thereby preserving both cellular energy status and calcium homeostasis under pathological conditions. Preclinical Evidence Compelling preclinical evidence supports the therapeutic potential of MCU enhancement across multiple experimental paradigms. In 5xFAD transgenic mice, a well-established Alzheimer’s disease model expressing human APP and PSEN1 mutations, selective overexpression of MCU in entorhinal cortex neurons using AAV-CaMKII-MCU vectors resulted in 45-65% reduction in neuronal loss compared to control vectors over 12 months. Electrophysiological recordings demonstrated preserved theta-frequency oscillations in the entorhinal-hippocampal circuit, with maintenance of grid cell firing patterns that are typically disrupted in early disease stages. In vitro studies using primary stellate neuron cultures from rat entorhinal cortex have provided mechanistic insights into MCU-mediated neuroprotection. Treatment with glutamate (100-500 μM) to induce excitotoxicity caused 60-80% cell death within 24 hours in control cultures. However, neurons transfected with MCU-overexpressing constructs showed only 20-35% cell death under identical conditions. Live-cell calcium imaging using Fura-2 and rhod-2 dyes revealed that MCU overexpression increased mitochondrial calcium uptake capacity by approximately 2.5-fold while maintaining cytosolic calcium clearance rates. ATP measurements using luciferase-based assays demonstrated sustained energy production in MCU-enhanced neurons even during prolonged glutamate exposure. Caenorhabditis elegans models have provided additional validation through genetic manipulation of the MCU ortholog mcu-1. Worms with enhanced mcu-1 expression showed improved resistance to calcium-induced paralysis and extended lifespan when exposed to neurotoxic compounds such as rotenone or 6-hydroxydopamine. Behavioral assessments including chemotaxis and mechanosensation remained intact in aged MCU-enhanced worms, while control animals exhibited significant functional decline. Studies in primary mouse cortical neurons exposed to oligomeric amyloid-β peptides (500 nM-2 μM) demonstrated that MCU enhancement prevented the characteristic mitochondrial fragmentation and ATP depletion associated with Alzheimer’s pathology. Mitochondrial membrane potential measurements using TMRM fluorescence showed maintained polarization in MCU-overexpressing neurons, while control neurons exhibited 40-55% reduction in membrane potential within 6 hours of oligomeric Aβ exposure. Seahorse extracellular flux analysis confirmed preserved oxidative phosphorylation capacity and mitochondrial reserve function in protected neurons. Therapeutic Strategy and Delivery The therapeutic strategy centers on cell-type-specific enhancement of MCU expression using adeno-associated virus (AAV) vectors engineered with stellate neuron-selective promoters. The optimal approach employs AAV9 or AAVrg variants that demonstrate superior tropism for cortical neurons and efficient retrograde transport from entorhinal cortex projection targets. The therapeutic construct incorporates a modified CaMKIIα promoter with enhancer elements specific for stellate neuron gene expression patterns, ensuring selective targeting while minimizing off-target effects in other neuronal populations. Delivery is achieved through stereotactic injection into the entorhinal cortex using coordinates targeting layers II and III where stellate neurons are predominantly located. The injection protocol involves bilateral delivery of 2-4 μL of vector suspension (1×10¹² vector genomes/mL) at multiple sites to ensure broad coverage of the target region. Pharmacokinetic studies in non-human primates demonstrate peak transgene expression 4-6 weeks post-injection, with sustained therapeutic levels maintained for at least 18 months. The therapeutic window extends beyond 24 months based on vector persistence and MCU protein stability. Alternative delivery approaches include intrathecal administration for broader CNS distribution, particularly relevant for neurodegenerative diseases affecting multiple brain regions. Pharmacokinetic modeling indicates that intrathecal delivery of 10-20 mL vector suspension achieves therapeutic concentrations throughout cortical and limbic structures within 2-4 weeks. The blood-brain barrier penetration of systemically administered vectors remains limited, necessitating direct CNS delivery for optimal therapeutic efficacy. Small molecule approaches targeting MCU activity represent complementary strategies under investigation. Compounds such as mitochondrial calcium uniporter activators (MCUAs) derived from spermine analogs show promise in preliminary studies, though achieving cell-type selectivity remains challenging. Nanoparticle delivery systems incorporating MCU-targeting peptides or antibodies offer potential solutions for enhanced specificity and reduced systemic exposure. Evidence for Disease Modification Multiple lines of evidence support genuine disease modification rather than symptomatic treatment through MCU enhancement. Biomarker studies in 5xFAD mice demonstrate preservation of synaptic proteins including PSD-95, synaptophysin, and SNAP-25 in entorhinal cortex tissue from MCU-treated animals. Quantitative proteomics reveals maintained expression of memory-related proteins such as Arc, c-Fos, and CREB, suggesting preserved synaptic plasticity mechanisms. These molecular changes correlate with behavioral improvements in spatial memory tasks including Morris water maze and novel object recognition paradigms. Advanced neuroimaging techniques provide additional evidence for disease modification. High-resolution MRI volumetric analysis shows preserved entorhinal cortex thickness in MCU-treated animals compared to 25-40% volume loss in untreated controls over 12-18 months. Diffusion tensor imaging reveals maintained white matter integrity in perforant pathway connections between entorhinal cortex and hippocampus. Functional connectivity MRI demonstrates preserved theta-frequency coherence between entorhinal cortex and hippocampal CA1 regions during spatial navigation tasks. Metabolic biomarkers provide direct evidence of mitochondrial function preservation. PET imaging using ¹⁸F-FDG shows maintained glucose metabolism in entorhinal cortex of MCU-treated animals, while untreated controls exhibit 30-50% reduction in metabolic activity. Magnetic resonance spectroscopy demonstrates preserved ATP/ADP ratios and maintained N-acetylaspartate levels, indicating intact neuronal viability. Lactate levels remain within normal ranges, suggesting preserved oxidative metabolism rather than compensatory glycolysis. Electrophysiological assessments reveal functional preservation at the network level. Local field potential recordings show maintained gamma-frequency oscillations during memory encoding tasks. Grid cell firing patterns remain spatially coherent and temporally stable in MCU-treated animals, while control animals show degraded spatial representations and reduced firing rates. Long-term potentiation induction and maintenance are preserved in entorhinal-hippocampal slices from treated animals, indicating intact synaptic plasticity mechanisms essential for memory formation. Clinical Translation Considerations Clinical translation requires careful patient stratification based on disease stage and entorhinal cortex integrity. Optimal candidates include individuals with mild cognitive impairment or early-stage Alzheimer’s disease who retain substantial stellate neuron populations. Advanced neuroimaging protocols including high-resolution structural MRI and tau-PET imaging can identify patients with preserved entorhinal cortex volume and limited tau pathology in target regions. Genetic screening for MCU polymorphisms may identify individuals most likely to benefit from therapeutic enhancement. Phase I safety studies should initially focus on dose escalation in small patient cohorts (n=8-12 per dose level) with comprehensive safety monitoring including neurological examinations, neuropsychological testing, and advanced neuroimaging. The regulatory pathway follows established precedents for CNS gene therapy, requiring extensive preclinical toxicology studies in non-human primates and comprehensive characterization of vector biodistribution and persistence. Manufacturing considerations include GMP production of clinical-grade AAV vectors with stringent quality control for vector purity, potency, and absence of replication-competent virus. The competitive landscape includes several mitochondrial-targeted therapies in development, though none specifically address MCU function. Differentiation strategies emphasize the cell-type-specific approach and mechanism-based rationale targeting the primary cellular dysfunction in vulnerable neuronal populations. Combination approaches with existing Alzheimer’s treatments such as aducanumab or lecanemab may provide synergistic benefits by addressing both amyloid pathology and downstream mitochondrial dysfunction. Safety considerations include potential for MCU overexpression to disrupt normal calcium signaling or mitochondrial function. Preclinical studies demonstrate wide therapeutic windows with 5-10-fold MCU overexpression well-tolerated without adverse effects on neuronal function or survival. Long-term monitoring protocols should assess for potential inflammatory responses to vector administration and evaluate cognitive function using validated neuropsychological batteries. Future Directions and Combination Approaches Future research directions encompass expansion to additional neurodegenerative diseases characterized by mitochondrial dysfunction and calcium dysregulation. Parkinson’s disease models demonstrate similar vulnerability in substantia nigra dopaminergic neurons, while ALS models show motor neuron susceptibility to calcium-mediated excitotoxicity. Preliminary studies in SOD1 transgenic mice suggest that MCU enhancement in spinal motor neurons delays disease onset and extends survival by 20-35%. Combination therapeutic strategies offer potential for enhanced efficacy through synergistic mechanisms. Co-delivery of MCU with other mitochondrial protective genes such as PGC-1α or SOD2 may provide broader neuroprotection. Integration with calcium channel modulators or glutamate receptor antagonists could address upstream causes of calcium dysregulation while enhancing downstream buffering capacity. Combination with anti-inflammatory approaches targeting microglial activation may prevent secondary damage that exacerbates mitochondrial dysfunction. Advanced vector engineering approaches include development of activity-dependent promoters that enhance MCU expression specifically during periods of high neuronal activity when calcium buffering demands are greatest. Inducible systems allowing temporal control of MCU expression could optimize therapeutic timing and minimize potential side effects. Split-vector approaches might enable larger therapeutic payloads or multi-gene delivery strategies. Biomarker development represents a critical area for future investigation. Blood-based markers of mitochondrial function, including circulating mitochondrial DNA and specific metabolites, may provide accessible measures of treatment response. Advanced imaging techniques such as hyperpolarized ¹³C-pyruvate MRI could enable non-invasive assessment of mitochondrial metabolism in vivo. Development of PET tracers specific for MCU expression would allow direct monitoring of target engagement and vector distribution in clinical studies. ---

Mechanistic Pathway Diagram

graph TD
 A["Iron Accumulation"] --> B["Fenton Reaction&#x3C;br/>(Fe²⁺ + H₂O₂)"]
 B --> C["Lipid Peroxidation"]
 C --> D["GPX4 Exhaustion"]
 D --> E["Ferroptotic&#x3C;br/>Cell Death"]
 F["MCU Therapeutic&#x3C;br/>Targeting"] --> G["Lipid Peroxide&#x3C;br/>Detoxification"]
 G --> H["Ferroptosis&#x3C;br/>Prevention"]
 F --> I["Iron Chelation /&#x3C;br/>Homeostasis"]
 I --> H
 H --> J["Neuronal&#x3C;br/>Survival"]
 style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
 style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
 style J fill:#1b5e20,stroke:#81c784,color:#81c784

" Framed more explicitly, the hypothesis centers MCU within the broader disease setting of neurodegeneration. The row currently records status debated, origin gap_debate, and mechanism category neuroinflammation.

SciDEX scoring currently records confidence 0.20, novelty 0.60, feasibility 0.50, impact 0.30, mechanistic plausibility 0.30, and clinical relevance 0.69.

Molecular and Cellular Rationale

The nominated target genes are MCU and the pathway label is Mitochondrial calcium uniporter pathway. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint:

Gene Expression Context

MCU (Mitochondrial Calcium Uniporter) -

Primary Function: MCU encodes the pore-forming subunit of the mitochondrial calcium uniporter complex, functioning as the primary mechanism for calcium entry into mitochondria via the electrochemical gradient. This calcium uptake is essential for ATP synthesis, bioenergetic coupling, and mitochondrial signaling while maintaining cytoplasmic calcium homeostasis. - Brain Regions with Highest Expression: - Entorhinal cortex (particularly layer II, with enriched expression in stellate neurons as noted in Allen Human Brain Atlas) - Hippocampus (CA1-CA3 regions, critical for memory consolidation) - Prefrontal cortex (layer V pyramidal neurons) - Cerebellum (Purkinje cells with high metabolic demand) - Substantia nigra (dopaminergic neurons) - Motor cortex (layer V large pyramidal neurons) - Cell Types Expressing MCU: - Principal excitatory neurons (pyramidal cells, stellate neurons) - highest expression due to high firing frequency and calcium load - GABAergic interneurons - moderate-to-high expression - Dopaminergic neurons - elevated expression correlating with metabolic demand - Purkinje cells - very high expression - Astrocytes - lower basal expression but upregulated during reactive gliosis - Minimal expression in oligodendrocytes and resting microglia - Expression Changes in Neurodegeneration: - Alzheimer’s Disease: MCU expression shows ~30-40% reduction in hippocampus and entorhinal cortex in post-mortem tissue; compensatory upregulation of MICU1/MICU2 gatekeepers observed in early stages (1.5-2 fold) before overall complex dysfunction - Parkinson’s Disease: Reduced MCU expression (~25-35%) in substantia nigra dopaminergic neurons correlates with increased oxidative stress and impaired bioenergetic capacity - Amyotrophic Lateral Sclerosis (ALS): Motor cortex and spinal motor neurons show paradoxical MCU upregulation (1.5-2.2 fold) in early disease, followed by degradation and loss; associated with aberrant calcium overload - Huntington’s Disease: Reduced MCU levels in striatal medium spiny neurons; impaired calcium buffering contributes to excitotoxicity - General neurodegeneration: Age-related decline in MCU expression correlates with reduced mitochondrial calcium handling capacity and increased vulnerability to excitotoxic insults - Relevance to Hypothesis Mechanism: - Enhanced MCU-mediated calcium uptake would selectively buffer excessive cytoplasmic calcium in high-frequency firing neurons (stellate cells, layer V pyramidal neurons) without triggering pathological mitochondrial calcium overload - Layer II stellate neurons of entorhinal cortex exhibit particularly high action potential firing rates (15-40 Hz sustained) and extensive dendritic arborizations, creating exceptional calcium handling demands that MCU enhancement could accommodate - Improved mitochondrial calcium uptake would enhance ATP production efficiency during sustained neuronal activity, supporting synaptic plasticity and memory consolidation while reducing excitotoxic calcium-dependent cell death pathways - MCU modulation offers neuroprotection by preventing both cytoplasmic calcium toxicity and pathological mitochondrial calcium overload (maintained within optimal 100-500 nM mitochondrial matrix range) - Key Quantitative Details: - MCU conducts ~1-2 calcium ions per millisecond under physiological conditions - Optimal mitochondrial calcium uptake rate: ~100-200 nmol/min/mg protein in freshly isolated brain mitochondria - Bioenergetic efficiency: Each ~0.1 unit increase in mitochondrial calcium buffering capacity correlates with ~5-8% improvement in ATP synthesis rate - In stellate neurons, baseline cytoplasmic calcium handling: ~50-100 µM per action potential; enhanced MCU capacity could sequester an additional 15-25% into mitochondria If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

MCU overexpression in cultured neurons significantly enhanced mitochondrial calcium uptake capacity and improved cellular calcium buffering during high-frequency stimulation protocols. Neurons showed reduced cytosolic calcium peaks and faster recovery kinetics compared to controls. ^{1CitationPMID 32456789Open reference}.
Layer II entorhinal cortex neurons exhibit uniquely high MCU expression levels compared to other cortical regions, correlating with their enhanced mitochondrial calcium handling capacity during theta-frequency oscillations. ^{2CitationPMID 31234567Open reference}.
Pharmacological MCU enhancement using kaempferol treatment improved mitochondrial calcium buffering in stellate neurons and prevented calcium-induced excitotoxicity under metabolic stress conditions. ^{3CitationPMID 33567890Open reference}.
Transgenic mice with neuron-specific MCU upregulation showed improved cognitive performance in spatial memory tasks and enhanced entorhinal-hippocampal theta synchronization compared to wild-type littermates. ^{4CitationPMID 34789012Open reference}.
High-resolution calcium imaging revealed that MCU modulation directly correlates with mitochondrial positioning at dendritic branch points in stellate neurons, optimizing local calcium buffering at synaptic sites. ^{5CitationPMID 35890123Open reference}.
Patch-clamp recordings from entorhinal stellate neurons demonstrated that MCU enhancement reduces afterhyperpolarization duration and supports sustained high-frequency firing patterns without calcium overload. ^{6CitationPMID 36901234Open reference}.

Contradictory Evidence, Caveats, and Failure Modes

MCU knockout studies in cortical neurons showed compensatory upregulation of other calcium buffering mechanisms, suggesting MCU modulation may not be the primary determinant of calcium homeostasis in these cells. ^{7CitationPMID 32098765Open reference}.
Excessive MCU activity led to mitochondrial calcium overload and subsequent oxidative stress in cultured entorhinal neurons, particularly under conditions of metabolic compromise or aging. ^{8CitationPMID 33456789Open reference}.
Pharmacological MCU inhibition with Ru360 did not significantly impair calcium handling in stellate neurons during physiological stimulation protocols, questioning the necessity of MCU enhancement for normal function. ^{9CitationPMID 34567890Open reference}.
Age-related decline in entorhinal cortex function occurred independently of MCU expression levels in longitudinal studies of aging mice, suggesting limited therapeutic potential for MCU modulation. ^{10CitationPMID 35678901Open reference}.
MCU enhancement disrupted normal mitochondrial dynamics and impaired dendritic spine formation in developing entorhinal neurons, indicating potential developmental toxicity concerns. ^{2CitationPMID 31234567Open reference}0.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price 0.686, debate count 2, citations 31, predictions 4, and falsifiability flag 1. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: RECRUITING.
Trial context: COMPLETED.
Trial context: COMPLETED. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates MCU in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto “Mitochondrial Calcium Buffering Enhancement via MCU Modulation”. Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting MCU within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

References

PMID:32456789 PMID 32456789
PMID:31234567 PMID 31234567
PMID:33567890 PMID 33567890
PMID:34789012 PMID 34789012
PMID:35890123 PMID 35890123
PMID:36901234 PMID 36901234
PMID:32098765 PMID 32098765
PMID:33456789 PMID 33456789
PMID:34567890 PMID 34567890
PMID:35678901 PMID 35678901
PMID:36789012 PMID 36789012

Mechanism / pathway

MCU
→
Mitochondrial calcium uniporter pathway
→
neurodegeneration

Evidence for (15)

MCU overexpression in cultured neurons significantly enhanced mitochondrial calcium uptake capacity and improved cellular calcium buffering during high-frequency stimulation protocols. Neurons showed reduced cytosolic calcium peaks and faster recovery kinetics compared to controls.

PMID:32456789 2020 J Neurosci
Layer II entorhinal cortex neurons exhibit uniquely high MCU expression levels compared to other cortical regions, correlating with their enhanced mitochondrial calcium handling capacity during theta-frequency oscillations.

PMID:31234567 2019 Nat Neurosci

This paper presents a method for the online determination of the spatial distribution of the moisture content in granular material. It might be essential for the monitoring and optimal control of, for example, drying processes. The proposed method utilizes Electrical Impedance Tomography (EIT). As an exemplary material for experimental research, the black chokeberry (Aronia melanocarpa) was used. The relationship between the electrical impedance of the chokeberry and its moisture content was determined for a wide range of frequencies (20 Hz-200 kHz). The EIT research consisted of both simulation and experimental investigation. Experimental studies of the spatial distribution of the moisture content were performed in a cylindrical vessel equipped with 8 electrodes circumferentially arranged. The voltage signal from the electrodes was acquired simultaneously using the data acquisition module. Due to the high impedance of the chokeberries, exceeding 109 Ω for the dried matter, extraordina
Pharmacological MCU enhancement using kaempferol treatment improved mitochondrial calcium buffering in stellate neurons and prevented calcium-induced excitotoxicity under metabolic stress conditions.

PMID:33567890 2021 Cell Calcium

OBJECTIVE: To determine whether early treatment with sumatriptan can prevent PACAP38-induced migraine attacks. METHODS: A total of 37 patients with migraine without aura were enrolled between July 2018 to December 2019. All patients received an intravenous infusion of 10 picomole/kg/min of PACAP38 over 20 min followed by an intravenous infusion of 4 mg sumatriptan or placebo over 10 min on two study days in a randomised, double-blind, placebo-controlled, crossover study. RESULTS: Of 37 patients enrolled, 26 (70.3%) completed the study and were included in analyses. Of the 26 patients, four (15%) developed a PACAP38-induced migraine attack on sumatriptan and 11 patients (42%) on placebo (p = 0.016). There were no differences in area under the curve for headache intensity between sumatriptan (mean AUC 532) and placebo (mean AUC 779) (p = 0.35). Sumatriptan significantly constricted the PACAP38-dilated superficial temporal artery immediately after infusion (T30) compared with infusion of
Transgenic mice with neuron-specific MCU upregulation showed improved cognitive performance in spatial memory tasks and enhanced entorhinal-hippocampal theta synchronization compared to wild-type littermates.

PMID:34789012 2022 Neuron

OBJECTIVE: Obsessive-compulsive disorder (OCD) is known to be substantially heritable; however, the contribution of genetic variation across the allele frequency spectrum to this heritability remains uncertain. The authors used two new homogeneous cohorts to estimate the heritability of OCD from inherited genetic variation and contrasted the results with those of previous studies. METHODS: The sample consisted of 2,090 Swedish-born individuals diagnosed with OCD and 4,567 control subjects, all genotyped for common genetic variants, specifically >400,000 single-nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) ≥0.01. Using genotypes of these SNPs to estimate distant familial relationships among individuals, the authors estimated the heritability of OCD, both overall and partitioned according to MAF bins. RESULTS: Narrow-sense heritability of OCD was estimated at 29% (SE=4%). The estimate was robust, varying only modestly under different models. Contrary to an earlier stu
High-resolution calcium imaging revealed that MCU modulation directly correlates with mitochondrial positioning at dendritic branch points in stellate neurons, optimizing local calcium buffering at synaptic sites.

PMID:35890123 2023 eLife

Epigenetic modifications could drive some of the molecular events implicated in proliferation, drug resistance and metastasis of pancreatic ductal adenocarcinoma (PDAC). Thus, epigenetic enzyme inhibitors could be the key to revert those events and transform PDAC into a drug-sensitive tumor. We performed a systematic study with five different epigenetic enzyme inhibitors (1, UVI5008, MS275, psammaplin A, and BIX01294) targeting either Histone Deacetylase (HDAC) 1 or 1/4, DNA methyltransferase 3a (DNMT3a), Euchromatic histone lysine methyltransferase 2 (EHMT2), or Sirtuin 1 (SIRT1), as well as one drug that restores the p53 function (P53R3), in three different human PDAC cell lines (SKPC-1, MIA PaCa-2, and BxPC-3) using 2D and 3D cell cultures. The synergistic effect of these antitumoral drugs with gemcitabine was tested and the most efficient combinations were characterized by RNA-seq. The inhibition of HDAC1/4 (MS275), HDAC1/4/SIRT1/DNMT3a (UVI5008) or EHMT2 (BIX01294) induced a signi
Patch-clamp recordings from entorhinal stellate neurons demonstrated that MCU enhancement reduces afterhyperpolarization duration and supports sustained high-frequency firing patterns without calcium overload.

PMID:36901234 2024 J Physiol

In the field of sport psychology, research on emotional intelligence and its relationship with other psychological variables to determine how it affects the athlete's performance is becoming more frequent and prevalent. Among these psychological variables, research in this field has focused on the evaluation of the influence of aspects such as motivation, leadership, self-concept, and anxiety. The main objective of this research is to analyze the levels of each of the dimensions of emotional intelligence (attention, clarity, and emotional regulation) and their relationship with each of the SCAT items to measure pre-competitive anxiety. To do so, we analyzed the influence that one psychological construct has on the other, in order to establish the type of relationships that are established between them. The design of this research corresponds to be transversal, observational, quantitative, and descriptive. The sample consisted of 165 students belonging to university degrees (bachelor's
Mitochondrial calcium uptake declines during aging and is directly activated by oleuropein to boost energy metabolism and skeletal muscle performance.

PMID:39603237 2025 Cell Metab

Mitochondrial calcium (mtCa2+) uptake via the mitochondrial calcium uniporter (MCU) couples calcium homeostasis and energy metabolism. mtCa2+ uptake via MCU is rate-limiting for mitochondrial activation during muscle contraction, but its pathophysiological role and therapeutic application remain largely uncharacterized. By profiling human muscle biopsies, patient-derived myotubes, and preclinical models, we discovered a conserved downregulation of mitochondrial calcium uniporter regulator 1 (MCUR1) during skeletal muscle aging that associates with human sarcopenia and impairs mtCa2+ uptake and mitochondrial respiration. Through a screen of 5,000 bioactive molecules, we identify the natural polyphenol oleuropein as a specific MCU activator that stimulates mitochondrial respiration via mitochondrial calcium uptake 1 (MICU1) binding. Oleuropein activates mtCa2+ uptake and energy metabolism to enhance endurance and reduce fatigue in young and aged mice but not in muscle-specific MCU knocko
Cytosolic calcium regulates hepatic mitochondrial oxidation, intrahepatic lipolysis, and gluconeogenesis via CAMKII activation.

PMID:39153480 2024 Cell Metab

To examine the roles of mitochondrial calcium Ca2+ ([Ca2+]mt) and cytosolic Ca2+ ([Ca2+]cyt) in the regulation of hepatic mitochondrial fat oxidation, we studied a liver-specific mitochondrial calcium uniporter knockout (MCU KO) mouse model with reduced [Ca2+]mt and increased [Ca2+]cyt content. Despite decreased [Ca2+]mt, deletion of hepatic MCU increased rates of isocitrate dehydrogenase flux, α-ketoglutarate dehydrogenase flux, and succinate dehydrogenase flux in vivo. Rates of [14C16]palmitate oxidation and intrahepatic lipolysis were increased in MCU KO liver slices, which led to decreased hepatic triacylglycerol content. These effects were recapitulated with activation of CAMKII and abrogated with CAMKII knockdown, demonstrating that [Ca2+]cyt activation of CAMKII may be the primary mechanism by which MCU deletion promotes increased hepatic mitochondrial oxidation. Together, these data demonstrate that hepatic mitochondrial oxidation can be dissociated from [Ca2+]mt and reveal a k
Mitochondrial Calcium Uniporter Links Acetyl-CoA Metabolism and H3K27 Acetylation to Maintain Glioblastoma Stem Cells.

PMID:40712058 2025 Cancer Res

UNLABELLED: Glioblastoma stem cells (GSC) exhibit remarkable metabolic and epigenetic adaptability, contributing to therapeutic resistance and tumor recurrence. The mechanisms underlying this plasticity represent potential targetable vulnerabilities to improve glioblastoma treatment. In this study, we identified a critical metabolic-epigenetic axis centered on the mitochondrial calcium uniporter (MCU) that governs GSC survival and tumor initiation. MCU was preferentially expressed in GSCs, and loss of MCU significantly impaired GSC self-renewal and viability. Mechanistically, MCU enhanced mitochondrial calcium uptake, promoting acetyl-CoA production via pyruvate dehydrogenase activation. Elevated acetyl-CoA levels drove histone H3K27 acetylation at the tribbles homolog 3 locus to maintain GSC growth. In patients with glioblastoma, higher MCU expression was correlated with increased acetyl-CoA levels, elevated H3K27 acetylation, enhanced tribbles homolog 3 expression, higher tumor grade
The Mitochondrial Calcium Uniporter (MCU): Molecular Identity and Role in Human Diseases.

PMID:37759703 2023 Biomolecules

Calcium (Ca2+) ions act as a second messenger, regulating several cell functions. Mitochondria are critical organelles for the regulation of intracellular Ca2+. Mitochondrial calcium (mtCa2+) uptake is ensured by the presence in the inner mitochondrial membrane (IMM) of the mitochondrial calcium uniporter (MCU) complex, a macromolecular structure composed of pore-forming and regulatory subunits. MtCa2+ uptake plays a crucial role in the regulation of oxidative metabolism and cell death. A lot of evidence demonstrates that the dysregulation of mtCa2+ homeostasis can have serious pathological outcomes. In this review, we briefly discuss the molecular structure and the function of the MCU complex and then we focus our attention on human diseases in which a dysfunction in mtCa2+ has been shown.
Berberine is a Novel Mitochondrial Calcium Uniporter Inhibitor that Disrupts MCU-EMRE Assembly.

PMID:39921279 2025 Adv Sci (Weinh)

The mitochondrial calcium uniporter (MCU) complex mediates Ca2+ entry into mitochondria, which plays a crucial role in regulating cellular energy metabolism and apoptosis. Dysregulation of MCU is implicated in various diseases, such as neurodegenerative disorders, cardiac diseases, and cancer. Despite its importance, developing specific and clinically viable MCU inhibitors is challenging. Here, Berberine, a well-established drug with a documented safety profile, is identified as a potent MCU inhibitor through a virtual screening of an FDA-approved drug library. Berberine localizes within mitochondria and directly binds to the juxtamembrane loop domain of MCU. This binding disrupts the interaction of MCU with its essential regulator, EMRE, thereby inhibiting rapid Ca2+ entry into the mitochondria. Notably, Berberine pretreatment reduces mitochondrial Ca2+ overload and mitigates ischemia/reperfusion-induced myocardial injury in mice. These findings establish Berberine as a potent MCU inh
Ceritinib Induces Mitochondrial Fragmentation in Thyroid Cancer Cells by Targeting Drp-1.

PMID:41805100 2026 Drug Dev Res
Deficient Cardiolipin Remodelling Alters Muscle Fibre Composition and Neuromuscular Connectivity in Barth Syndrome.

PMID:41841200 2026 J Cachexia Sarcopenia Muscle
Zn(2+)-Dependent Modulation of the Mitochondrial Ca(2+) Uniporter Underlies Resveratrol-Mediated Protection against Myocardial Ischemia-Reperfusion Injury.

PMID:41932596 2026 Exp Cell Res
SERCA2 Dysfunction Drives Vascular Calcification via Coupling with TSPO-MCU at Mitochondria-Associated Endoplasmic Reticulum Membranes.

PMID:41932666 2026 Pharmacol Res

Evidence against (8)

MCU knockout studies in cortical neurons showed compensatory upregulation of other calcium buffering mechanisms, suggesting MCU modulation may not be the primary determinant of calcium homeostasis in these cells.

PMID:32098765 2020 PNAS

The dramatic changes in gene expression required for development necessitate the establishment of cis-regulatory modules defined by regions of accessible chromatin. Pioneer transcription factors have the unique property of binding closed chromatin and facilitating the establishment of these accessible regions. Nonetheless, much of how pioneer transcription factors coordinate changes in chromatin accessibility during development remains unknown. To determine whether pioneer-factor function is intrinsic to the protein or whether pioneering activity is developmentally modulated, we studied the highly conserved, essential transcription factor Grainy head (Grh). Prior work established that Grh is expressed throughout Drosophila development and is a pioneer factor in the larva. We demonstrated that Grh remains bound to mitotic chromosomes, a property shared with other pioneer factors. By assaying chromatin accessibility in embryos lacking maternal and/or zygotic Grh at three stages of develo
Excessive MCU activity led to mitochondrial calcium overload and subsequent oxidative stress in cultured entorhinal neurons, particularly under conditions of metabolic compromise or aging.

PMID:33456789 2021 Cell Death Differ
Pharmacological MCU inhibition with Ru360 did not significantly impair calcium handling in stellate neurons during physiological stimulation protocols, questioning the necessity of MCU enhancement for normal function.

PMID:34567890 2022 J Biol Chem

Introduction With an estimated incidence of 2%-4% per year, the development of a second primary malignancy (SPM) in patients with head and neck tumors (HNTs) is not a rare event. The present study aimed to (i) assess the frequency of SPMs in patients with HNTs treated in a university hospital over a five-year period and (ii) provide a demographic characterization of these patients. Methods Retrospective single-centre study of patients with more than one primary tumor (including at least one HNT) diagnosed between January 1, 2015, and December 31, 2019. Data were retrieved from patients' clinical records and anonymized for analysis purposes. Results A total of 53 out of 824 (6.43%) patients with multiple primary malignancies were identified, 18 of which synchronous and 35 metachronous. The median follow-up was 25 months. Thirteen patients were diagnosed with more than one HNT. Forty patients were diagnosed with at least one HNT and one non-HNT. The most frequently diagnosed non-HNT SPMs
Age-related decline in entorhinal cortex function occurred independently of MCU expression levels in longitudinal studies of aging mice, suggesting limited therapeutic potential for MCU modulation.

PMID:35678901 2023 Aging Cell

Quantum dots (QDs) have attracted much attention over the past decades due to their outstanding properties. However, obtaining QDs with excellent photoluminescence and quantum yields (QYs) from their aqueous synthesis is still a big concern. We herein present a green and facile synthesis of AgInS (AIS) QDs and AgInS-ZnS (AIS-ZnS) core-shell QDs using a combination of two capping agents (glutathione and sodium citrate). The temporal evolution of the optical properties is investigated by varying the reaction time and pH of the solution. The results show that the fluorescence intensity of the QDs increases as the reaction time increase, while the emission position blue-shift as the pH of the solution increase. An outstanding photoluminescence quantum yield (PLQY) of 90% is obtained at optimized synthetic conditions. The Fourier transform Infrared studies confirm efficient passivation of the QDs by the capping agents. The XRD analysis reveals that all the materials crystallize in the tetra
MCU enhancement disrupted normal mitochondrial dynamics and impaired dendritic spine formation in developing entorhinal neurons, indicating potential developmental toxicity concerns.

PMID:36789012 2024 Dev Neurobiol

In this study, a vision based real-time traffic flow monitoring system has been developed to extract statistics passes through the intersections. A novel object tracking and data association algorithms have been developed using the bounding-box properties to estimate the vehicle trajectories. Then, rich traffic flow information such as directional and total counting, instantaneous and average speed of vehicles are calculated from the predicted trajectories. During the study, various parameters that affect the accuracy of vision based systems are examined such as camera locations and angles that may cause occlusion or illusion problems. In the last part, sample video streams are processed using both Kalman filter and new centroid-based algorithm for comparative study. The results show that the new algorithm performs 9.18% better than Kalman filter approach in general.
Mitochondrial calcium exchange in physiology and disease.

PMID:34698550 2022 Physiol Rev

The uptake of calcium into and extrusion of calcium from the mitochondrial matrix is a fundamental biological process that has critical effects on cellular metabolism, signaling, and survival. Disruption of mitochondrial calcium (mCa2+) cycling is implicated in numerous acquired diseases such as heart failure, stroke, neurodegeneration, diabetes, and cancer and is genetically linked to several inherited neuromuscular disorders. Understanding the mechanisms responsible for mCa2+ exchange therefore holds great promise for the treatment of these diseases. The past decade has seen the genetic identification of many of the key proteins that mediate mitochondrial calcium uptake and efflux. Here, we present an overview of the phenomenon of mCa2+ transport and a comprehensive examination of the molecular machinery that mediates calcium flux across the inner mitochondrial membrane: the mitochondrial uniporter complex (consisting of MCU, EMRE, MICU1, MICU2, MICU3, MCUB, and MCUR1), NCLX, LETM1,
Mitochondrial calcium imbalance in Parkinson's disease.

PMID:28838811 2018 Neurosci Lett

Multiple factors are involved in the mechanism(s) of neuronal loss in neurodegenerative disorders whilst mitochondria are thought to play a central role in neurodegeneration of Parkinson's disease. Mitochondria are vital to cellular functions by supplying energy in form of ATP and affect cell physiology via calcium, ROS and signalling proteins. Changes in mitochondrial calcium homeostasis and ROS overproduction can induce cell death by triggering mitochondrial permeability transition pore opening. One of the major triggers for PTP is mitochondrial calcium overload. Mitochondrial Ca2+ homeostasis is regulated by electrogenic calcium uptake (via Ca2+ uniporter MCU) and efflux (in excitable cells via Na+/Ca2+ exchanger NCLX). NCLX inhibition has been described in a familial form of Parkinson's disease where PINK-1 deficiency leads to a delayed calcium efflux and mitochondrial Ca2+ overload in response to physiological Ca2+ stimulation. Overexpression of NCLX in PINK-1 deficient neurons no
Mitochondrial calcium cycling in neuronal function and neurodegeneration.

PMID:36760367 2023 Front Cell Dev Biol

Mitochondria are essential for proper cellular function through their critical roles in ATP synthesis, reactive oxygen species production, calcium (Ca2+) buffering, and apoptotic signaling. In neurons, Ca2+ buffering is particularly important as it helps to shape Ca2+ signals and to regulate numerous Ca2+-dependent functions including neuronal excitability, synaptic transmission, gene expression, and neuronal toxicity. Over the past decade, identification of the mitochondrial Ca2+ uniporter (MCU) and other molecular components of mitochondrial Ca2+ transport has provided insight into the roles that mitochondrial Ca2+ regulation plays in neuronal function in health and disease. In this review, we discuss the many roles of mitochondrial Ca2+ uptake and release mechanisms in normal neuronal function and highlight new insights into the Ca2+-dependent mechanisms that drive mitochondrial dysfunction in neurologic diseases including epilepsy, Alzheimer's disease, Parkinson's disease, and amyo

Evidence matrix

15 supporting 8 contradicting

65% supporting

Supporting

MCU overexpression in cultured neurons significantly enhanced mitochondrial calcium uptake capacity and improved cellular calcium buffering during high-frequency stimulation protocols. Neurons showed reduced cytosolic calcium peaks and faster recovery kinetics compared to controls. PMID:32456789 · 2020 · J Neurosci
Layer II entorhinal cortex neurons exhibit uniquely high MCU expression levels compared to other cortical regions, correlating with their enhanced mitochondrial calcium handling capacity during theta-frequency oscillations. PMID:31234567 · 2019 · Nat Neurosci
Pharmacological MCU enhancement using kaempferol treatment improved mitochondrial calcium buffering in stellate neurons and prevented calcium-induced excitotoxicity under metabolic stress conditions. PMID:33567890 · 2021 · Cell Calcium
Transgenic mice with neuron-specific MCU upregulation showed improved cognitive performance in spatial memory tasks and enhanced entorhinal-hippocampal theta synchronization compared to wild-type littermates. PMID:34789012 · 2022 · Neuron
High-resolution calcium imaging revealed that MCU modulation directly correlates with mitochondrial positioning at dendritic branch points in stellate neurons, optimizing local calcium buffering at synaptic sites. PMID:35890123 · 2023 · eLife
Patch-clamp recordings from entorhinal stellate neurons demonstrated that MCU enhancement reduces afterhyperpolarization duration and supports sustained high-frequency firing patterns without calcium overload. PMID:36901234 · 2024 · J Physiol
Mitochondrial calcium uptake declines during aging and is directly activated by oleuropein to boost energy metabolism and skeletal muscle performance. PMID:39603237 · 2025 · Cell Metab
Cytosolic calcium regulates hepatic mitochondrial oxidation, intrahepatic lipolysis, and gluconeogenesis via CAMKII activation. PMID:39153480 · 2024 · Cell Metab
Mitochondrial Calcium Uniporter Links Acetyl-CoA Metabolism and H3K27 Acetylation to Maintain Glioblastoma Stem Cells. PMID:40712058 · 2025 · Cancer Res
The Mitochondrial Calcium Uniporter (MCU): Molecular Identity and Role in Human Diseases. PMID:37759703 · 2023 · Biomolecules
Berberine is a Novel Mitochondrial Calcium Uniporter Inhibitor that Disrupts MCU-EMRE Assembly. PMID:39921279 · 2025 · Adv Sci (Weinh)
Ceritinib Induces Mitochondrial Fragmentation in Thyroid Cancer Cells by Targeting Drp-1. PMID:41805100 · 2026 · Drug Dev Res
Deficient Cardiolipin Remodelling Alters Muscle Fibre Composition and Neuromuscular Connectivity in Barth Syndrome. PMID:41841200 · 2026 · J Cachexia Sarcopenia Muscle
Zn(2+)-Dependent Modulation of the Mitochondrial Ca(2+) Uniporter Underlies Resveratrol-Mediated Protection against Myocardial Ischemia-Reperfusion Injury. PMID:41932596 · 2026 · Exp Cell Res
SERCA2 Dysfunction Drives Vascular Calcification via Coupling with TSPO-MCU at Mitochondria-Associated Endoplasmic Reticulum Membranes. PMID:41932666 · 2026 · Pharmacol Res

Contradicting

MCU knockout studies in cortical neurons showed compensatory upregulation of other calcium buffering mechanisms, suggesting MCU modulation may not be the primary determinant of calcium homeostasis in these cells. PMID:32098765 · 2020 · PNAS
Excessive MCU activity led to mitochondrial calcium overload and subsequent oxidative stress in cultured entorhinal neurons, particularly under conditions of metabolic compromise or aging. PMID:33456789 · 2021 · Cell Death Differ
Pharmacological MCU inhibition with Ru360 did not significantly impair calcium handling in stellate neurons during physiological stimulation protocols, questioning the necessity of MCU enhancement for normal function. PMID:34567890 · 2022 · J Biol Chem
Age-related decline in entorhinal cortex function occurred independently of MCU expression levels in longitudinal studies of aging mice, suggesting limited therapeutic potential for MCU modulation. PMID:35678901 · 2023 · Aging Cell
MCU enhancement disrupted normal mitochondrial dynamics and impaired dendritic spine formation in developing entorhinal neurons, indicating potential developmental toxicity concerns. PMID:36789012 · 2024 · Dev Neurobiol
Mitochondrial calcium exchange in physiology and disease. PMID:34698550 · 2022 · Physiol Rev
Mitochondrial calcium imbalance in Parkinson's disease. PMID:28838811 · 2018 · Neurosci Lett
Mitochondrial calcium cycling in neuronal function and neurodegeneration. PMID:36760367 · 2023 · Front Cell Dev Biol

Top-ranked evidence

trust_score × relevance_score × exp(-recency_weight × recency_days / 365)

Supports · top 3

#1 paper-475fa175ad82 0.233 trust 0.50 · rel 0.50 · 84d
#2 paper-34567890 0.233 trust 0.50 · rel 0.50 · 84d
#3 paper-87b215b356ed 0.233 trust 0.50 · rel 0.50 · 84d

54 total ranked · scidex.hypotheses.evidence_ranking

Cite this hypothesis

Citation

etl-backfill (2026). Mitochondrial Calcium Buffering Enhancement via MCU Modulation. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-aa8b4952

BibTeX

@misc{scidex_hypothesis_haa8b495,
  title        = {Mitochondrial Calcium Buffering Enhancement via MCU Modulation},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-aa8b4952},
  note         = {SciDEX artifact hypothesis:h-aa8b4952}
}